The combination of mass spectrometry and quantitative proteomics are promising strategies for discovering potential biomarkers. We were able to identify proteins that are differentially expressed in TBM. The differential proteins were validated in 15 TBM cases by IHC which correlated with iTRAQ experimental results. Further investigation of these candidate markers should reveal the molecular mechanisms involved in host pathogen interactions and may lead to the development of an efficient diagnostic and therapeutic approaches for reducing mortality and morbidity in TBM.
展开▼
